Scleroderma Clinical Trial
— CAMPATH-1HOfficial title:
Campath-1h as Immunoablative Therapy for Children and Adolescents With Treatment Refractory Systemic Sclerosis
NCT number | NCT01639573 |
Other study ID # | CCI-11-00077 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | April 2011 |
Est. completion date | September 2, 2018 |
Verified date | September 2023 |
Source | Children's Hospital Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This phase I/II pilot trial seeks to demonstrate that prolonged administration of Campath-1H without prior marrow or stem cell harvesting can result in immunoablation similar to that achieved by hematopoietic stem cell transplantation (HSCT) from either bone marrow or peripheral blood stem cell sources in children and adolescents with severe treatment refractory systemic sclerosis (SSc).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2, 2018 |
Est. primary completion date | August 2, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 18 Years |
Eligibility | 4.2 Inclusion/Exclusion criteria 4.2.1 Inclusion criteria - 8 to 21 years of age, inclusive - Diffuse, cutaneous dcSSc as defined by the ACR criteria with evidence of active inflammatory disease. - Plus at least 1 of the following: - dcSSc-related pulmonary disease with forced vital capacity (FVC) or hemoglobin-adjusted DLCO < 70% and evidence of alveolitis by high-resolution CT scan or bronchoalveolar lavage OR o History of SSc-related renal crisis or disease, not active at the time of screening OR - Moderate to severe upper and/or lower gastrointestinal involvement AND - Unacceptable toxicity or steroid dependence > 0.3 mg/kg/d - Failure to respond to, or unacceptable toxicity of MTX > 1mg/kg in combination with cyclosporine or azathioprine or cyclophosphamide or Rituximab 375 mg/m2 x 4 doses or Imatinib 800 mg/d or tocilizumab 8 mg/kg for at least 3 doses. - Disease recurrence after tapering medication above (in #4) 4.2.2 Exclusion Criteria - Pulmonary, cardiac, hepatic, or renal impairment that would limit therapy and compromise survival includes, but is not restricted to, any of the following: - Severe pulmonary dysfunction: hemoglobin-corrected DLCO < 45%, DLCO <4 mL/mmHg/min/L or pO2 < 70 mm Hg or pCO2, = 45 mm Hg without supplemental O2 sat 92% at rest without supplemental O2 - Significant pulmonary hypertension - Uncontrolled clinically significant arrhythmias - NYHA heart failure class IV - LVEF < 50% by echo or prior insertion of a pacemaker or cardioverter-defibrillator - End-stage renal disease (GFR<50 ml/min/1.73 m2 or creatinine . 2 mg/dl; estimated CrCl < 40 mL/min or active, untreated dcSSc renal crisis at time of enrollment - Active hepatitis (ALT, AST, or bilirubin > 2x ULN) - Active gastric antral vascular ectasia (GAVE, "watermelon stomach") - 2 mg/kg/day prednisone or equivalent within 30 days of treatment - Unwilling or unable to discontinue DMARDs for treatment of dcSSc - Co-morbid illnesses with an estimated median life expectancy < 5 Years - Active uncontrolled infection - Positive serology for hepatitis B or C, HIV - ANC < 1500 cells/µL, platelets < 120,000 cells/µL, Hct < 27% or Hgb < 9.0 g/dL - Malignancy within the previous 2 years, excluding treated skin cancer - Myelodysplasia - Uncontrolled hypertension - History of hypersensitivity to murine or E. coli proteins - Pregnancy or unwilling to use contraceptive methods for at least 15 months - Steroid dependence: > 2mg/kg/day, prednisone or equivalent within 30 days prior to treatment - History of substance abuse within the last 5 years - History or presence of 2nd autoimmune disease requiring immunosuppressive therapy that has a substantial risk of recurrence - Demonstrated lack of compliance with prior medical care - Lack of rehabilitation potential 4.3 SSc patients, who fulfill the inclusion criteria, will then be assessed for residual thymic function since our previous study of pediatric dcSSc patients demonstrated that the dcSSc patients had decreased thymic function as compared to age matched controls as measured by the proportion of naïve CD4+ T lymphocytes (CD4+, CD31+), recent thymic emigrants (RTE). (5) Patients with less than 40% RTE will be excluded because of concerns about their ability to reconstitute their immune system after immune ablation. 4.4 dcSSc patients, who fulfill the screening criteria, will be consented for entry into the clinical trial. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital Los Angeles |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary outcome | To determine why the extended administration of Campath-1H results in immune ablation in some patients and immunosuppression in others, Number of Participants with Adverse Events as a Measure of Safety and Tolerability Campath-1H antibody levels during and after the completion of the Campath administration. (47) Thus, both the peak Campath-1H levels as well as the duration of circulating Campath will be determined. | 2 years | |
Primary | Campath | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | The site will follow patients for 6 months post adverse event. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798055 -
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
|
||
Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT02915835 -
Riociguat in Scleroderma Associated Digital Ulcers
|
Phase 2 | |
Active, not recruiting |
NCT01895244 -
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
|
Phase 2 | |
Completed |
NCT00883129 -
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
|
Phase 2 | |
Completed |
NCT00930683 -
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
|
Phase 1 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Recruiting |
NCT04797286 -
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
|
Phase 2 | |
Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT03207997 -
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
|
N/A | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A | |
Completed |
NCT05080738 -
Upper Extremity Home Exercises in Patients With Scleroderma
|
N/A | |
Recruiting |
NCT03726398 -
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
|
Phase 2/Phase 3 | |
Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
Completed |
NCT02062125 -
Calcinosis in a Single-Center Scleroderma Population
|
||
Completed |
NCT04588714 -
Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT02835196 -
Optical Elastography of Systemic Sclerosis Skin
|